On 4 November 2026 Google published a whitepaper on evaluating AI for health use cases, with Dr. Elizabeth McGlynn and Dr. Dana Gelb Safran. The framework covers accuracy, safety and usefulness, combining closed-question benchmarks, autoraters and expert human review across common and high-risk journeys. Google says it already uses the method on its models and is sharing it for transparency with developers, researchers and clinicians.

What it means: For Greek health providers, telemedicine firms, insurers and startups embedding LLMs in patient information or clinical support, the takeaway is practical: without documented accuracy and safety evaluation, products face compliance and reputation risk. The benchmarks–autoraters–experts triad is a usable template for pre-production QA. It does not replace medical device approval or MDR/IVDR duties where they apply, nor health-data protection rules. It does help define critical user journeys, rejection criteria and post-launch monitoring. Vendors selling health AI to Greek clinics or pharmacies will more often be asked for evaluation methods, not demos alone. Legal and compliance teams can demand per-use-case risk maps and test archives. Operationally, invest in human oversight for high-risk queries and clear notices that the system is not a doctor. Publishing the method also reduces black-box friction in public-sector or large-provider procurement. In practice, teams should name an owner, update the risk register and agree success criteria within 30 days. Where suppliers or customers are affected, send a short notice that points to the primary source and avoids overstated claims. Compliance, cybersecurity and payments operations are linked; a change in one area often requires a pass over contracts, access rights and continuity plans. Finally, keep a review date so the item becomes concrete actions for the Greek business rather than newsletter noise alone.

Read the original on Google

Related service: Custom software

Related stories